Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q3 FY25 Earnings Presentation
20 slides from Themis Medicare's earnings presentation, Feb 14, 2025
Slide 1: Cover letter to stock exchanges: Investor Presentation
TML: CS: BSE/NSE CORR: 2024-25 14th February, 2025 The Manager The Manager – Listing Department Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Floor 25, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (East),
Slide 2: Result Update Presentation Q3 & 9M FY25
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q3 & 9M FY25
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 6: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “I would like to state that the Company’s performance in Q3FY25 and 9MFY25 remained in line with expectations. The continued growth of the Formulation segment reflects the efficient execution of the planned
Slide 7: Recent Development – Amalgamation of GTBL into Themis Medicare
Recent Development – Amalgamation of GTBL into Themis Medicare The recent board approval of amalgamation of GTBL into Themis Medicare would enable realisation of the following benefits: 01 Integration of the entire product value chain under a consolidated entity Consolidation will lead to synergies
Slide 8: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 123.0 30 117.0 23.7% 25% 97.8 93.8 25 29.2 20% 82.5 20 14.6% 15% 15 9.8% 9.5% 17.1 9.1% 10% 10 5 5% 8.1 9.3 8.5 0 0% Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3FY24 Q4FY24 Q1 FY25 Q2 FY25 Q3 FY25 PAT (Rs. C
Slide 9: Consolidated Quarterly Financial Highlights – Q3 FY25
Consolidated Quarterly Financial Highlights – Q3 FY25 Particulars (Rs. Cr.) Q3 FY25 Q3 FY24 Y-o-Y (%) Q2 FY25 • Formulation Segment has grown Net Revenue 93.81 82.51 13.69% 117.01 by 22% year-on-year for Q3 FY25 Cost of Material Consumed 12.76 21.13 21.06 Purchase of SIT 22.51 18.11 18.12 • Hospital
Slide 10: Consolidated Nine Months Financial Highlights – 9M FY25
Consolidated Nine Months Financial Highlights – 9M FY25 Particulars (Rs. Cr.) 9M FY25 9M FY24 Y-o-Y (%) Net Revenue 333.81 283.94 17.56% Cost of Material Consumed 57.33 63.02 Purchase of SIT 57.37 41.82 Changes in Inventory -3.30 -7.35 Employee Expenses 70.92 59.95 Other Expenses 96.65 84.30 Total E
Slide 11: Consolidated Balance Sheet as on 30th Sep'24
Consolidated Balance Sheet as on 30th Sep’24 As on 30th As on 31st As on 30th As on 31st Rs. Cr. Rs. Cr. Sep’24 Mar’24 Sep’24 Mar’24 Shareholders Funds 412.01 377.67 Non Current Assets 290.12 273.25 Share Capital 9.20 9.20 Plant, Property & Equipment 173.33 167.81 Other Equity 402.81 368.46 Capital
Slide 12: Company Overview
Company Overview
Slide 13: Snapshot of Company
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 36% to revenue in FY23-24 Total Debt to Equity at 0.25 in FY23-24 3 State of art manufacturing facilities in India – Rs. 2,422 Cr 1 Formulations and 2 APIs (S
Slide 14: Strong Business Model
Strong Business Model 01 Businesswise Revenue – 9M FY24-25 Hospital Business API, Co. Hospital is major growth 03 Mkt & 37% driver Others 42% Trade 21% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Intensive Care Division New Product pipeline Businesswise R
Slide 15: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 16: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14.25 13.64 13.69 R&D 11 7 10.00 Analytical Lab 8.50 7 8 Development Product in a year with 3.43 5–8 20-24 documentation FY19-20 FY20-21 FY21-22 FY22-23 FY23-24 9M FY25 Products in work rolli
Slide 17: Way Ahead
Way Ahead
Slide 18: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product Port
Slide 19: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 20: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Pradeep Chandan Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Adfactors PR Pvt Ltd Website: www.themismedicare.